• Combo Therapy for Advanced NSCLC Provides PFS Benefit

    1 month ago - By Medscape

    Combining a TKI with chemo or an antiangiogenic agent may prolong PFS in advanced NSCLC with certain mutations. The study was published as a preprint and has not yet been peer reviewed.
    First Look
    Read more ...

     

  • Long-Term Data Reinforce Targeted Combo Versus Single Agent for Advanced Melanoma

    Long-Term Data Reinforce Targeted Combo Versus Single Agent for Advanced Melanoma

    1 month ago - By MedPageToday

    Combination targeted therapy significantly improved 5-year progression-free survival and overall survival versus single-agent vemurafenib and was numerically superior to single-agent encorafenib (Braftovi...
    Read more ...